 |
10 Products |  |
2 Diseases | | 10 Products |
|
20 Trials |  |
746 News |  |
| «12345678910111213 |
- | ezutromid (SMT C1100) / Sarepta Therap
Trial completion: A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD) (clinicaltrials.gov) - Aug 27, 2014
P1, N=12, Completed, Sponsor: Summit Corporation Plc.
Recruiting --> Completed
- | Idefirix (imlifidase) / Hansa Biopharma, Sarepta Therap
New P2 trial, P2 data: Phase II Study, Evaluation of Safety and Efficacy of Immunoglobulin G Degrading Enzyme of Streptococcus Pyogenes (IdeS) in Chronic Kidney Disease (clinicaltrials.gov) - Aug 25, 2014
P2, N=12, Recruiting, Sponsor: Hansa Medical AB
- | ezutromid (SMT C1100) / Sarepta Therap
New P1 trial: A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD) (clinicaltrials.gov) - Feb 4, 2014
P1, N=12, Recruiting, Sponsor: Summit Corporation Plc.
- | Idefirix (imlifidase) / Hansa Biopharma, Sarepta Therap
New P1 trial: Safety Study on IdeS in Healthy Volounteers (clinicaltrials.gov) - Feb 27, 2013
P1, N=36, Recruiting, Sponsor: Hansa Medical AB
- | Exondys 51 (eteplirsen) / Sarepta Therap
Trial completion: Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients (clinicaltrials.gov) - Jan 21, 2013
P2, N=12, Completed, Sponsor: Sarepta Therapeutics
Recruiting --> Completed Active, not recruiting --> Completed
- | Exondys 51 (eteplirsen) / Sarepta Therap
New P2 trial: Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy (clinicaltrials.gov) - Feb 26, 2012
P2, N=12, Active, not recruiting, Sponsor: Sarepta Therapeutics